Company Has Holistic Approach for Diagnosing and Monitoring Sepsis

The major challenge for intensive care physicians is to be able to identify sepsis as early as possible to facilitate appropriate and effective treatment.

SIRS-Lab (Jena, Germany) has produced unique diagnostics for sepsis including Vyoo, which can run on any polymerase chain reaction (PCR) equipment, resulting in low investment and making it easy for laboratories to adopt. The test was granted the European CE marking in 2008. Besides Vyoo, SIRS- (Robotics and Systems)-Lab offers a pathogen DNA concentration system called Looxster for efficient sample preparation. The company's mission of "Decoding Sepsis” is now being met by the development of another key technology, "Siqnature,” a first-of-its-kind test for the early detection of sepsis through gene expression (transcriptome) profiling.

The Frost & Sullivan (San Antonio, TX, USA) "2009 European Molecular Diagnostics for Infectious Diseases Product Line Strategy of the Year Award," has been presented to SIRS-Lab, GmbH. The company's exceptional product line for sepsis diagnosis and monitoring make it a worthy recipient of this award. "SIRS-Lab is the first company in the market to introduce a holistic diagnostic approach for managing sepsis," remarked Frost & Sullivan research analyst Mr. Arun.

Mr. Arun added, "The ability to launch three major products in four years in the highly complex area of sepsis diagnostics shows the impressive strength of research and development at SIRS-Lab. This, combined with the company's constant effort to stay ahead in the market by strengthening its product portfolio, puts SIRS-Lab at the top of the market."

Frost & Sullivan is a growth partnership company. The company enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership.

Related Links:
SIRS-Lab
Frost & Sullivan